LYON, France, June 5, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced today that successful treatments have been performed at the St-Augustin Urology Clinic in Bordeaux, France utilizing EDAP's Ablatherm® High Intensity Focused Ultrasound (HIFU) for a focal approach to eradicate prostate cancer tumors.

Pierre Reboul, Sales Director of EDAP TMS France and UK Business Unit, commented, "We are very pleased that the St-Augustin Urology Clinic, a leading urology clinic in France and among the world's leaders in laparoscopic and robotic surgery, has utilized Ablatherm-HIFU as a therapeutic option for their prostate cancer patients. We are proud that this highly regarded urology practice is now positioning our Ablatherm-HIFU procedure as a 'must-have complement' to robotic surgery. We are confident that St-Augustin Urology Clinic is well positioned to become a leading reference center for focal therapy using Ablatherm-HIFU."

Dr. Thierry Piechaud, partner and urology surgeon at St-Augustin Urology Clinic, commented, "We are very enthusiastic about adding the Ablatherm-HIFU device to our therapeutic arsenal. We believe HIFU has developed a clear lead among other current technologies as a new approach and a modern concept of non-invasive treatment for early stage prostate cancer which preserves patient quality of life."

Marc Oczachowski, Chief Executive Officer of EDAP TMS, noted, "It is promising that such renowned surgery-oriented leaders have opted to use Ablatherm-HIFU for focal prostate cancer therapy. This is a significant recognition of HIFU's capability to complement surgical solutions for the treatment of early stage, localized prostate cancer, either as a focal or partial treatment. We continue to receive inquiries from well-known prostate surgeons that are interested in learning more about and seeking access to HIFU technology in the focal therapy field."

Mr. Oczachowski concluded, "Thanks to its unique precision and accuracy, repeatability, and non-invasiveness, combined with its ability to complement other therapies, Ablatherm-HIFU allows urologists to achieve the dual goals of controlling disease progression and preserving patients' quality of life. This is a new era in the treatment and management of localized prostate cancer."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm®, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

CONTACT: Blandine Confort

         Investor Relations / Legal Affairs

         EDAP TMS SA

         +33 4 72 15 31 72

         bconfort@edap-tms.com



         Investors:

         Stephanie CarringtonThe Ruth Group

         646-536-7017

         scarrington@theruthgroup.com

News Provided by Acquire Media